Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint Orion and ...

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That ...

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is ...

A meta-analysis involving 21,260 patients with advanced or metastatic prostate cancer confirms increased risks of falls and fractures with the addition of androgen receptor signaling inhibitors to ...

Purpose: Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue. These physical ...

The effectiveness of primary androgen-deprivation therapy (PADT) for clinically localized prostate cancer has been found lacking. A retrospective cohort study of more than 15,000 men newly diagnosed ...

Vasomotor symptoms (VMS) including hot flashes are a common complaint among men undergoing androgen deprivation therapy (ADT) for prostate cancer. Although the symptoms are more widely associated with ...

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as ...

Black patients were significantly more likely (38%) to experience incident MACE than White patients; and Black race was independently associated with a greater risk of heart failure, cerebrovascular ...

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is ...